Mark Stevenson Joins General Atlantic as Senior Advisor Focused on Life Sciences
25 March 2023 - 12:15AM
Business Wire
General Atlantic, a leading global growth equity firm, announced
today that Mark Stevenson has joined the firm as a Senior Advisor.
In his role, Mr. Stevenson will provide strategic counsel and
support to the firm’s investment teams and portfolio companies in
the Life Sciences sector.
Mr. Stevenson brings more than three decades of experience and
significant leadership experience in the sector, most recently
serving as Executive Vice President and Chief Operating Officer at
Thermo Fisher Scientific (NYSE: TMO), a Fortune 100 company
providing life science solutions, analytical instruments, specialty
diagnostics and pharma services with over $40B in sales annually.
He was responsible for the company’s portfolio of life science,
analytical and diagnostic businesses as well as the company’s
innovation and digital strategy. Mr. Stevenson currently serves as
a member of the company’s Scientific Advisory Board. He joined
Thermo Fisher in 2014 as President of Life Sciences Solutions
through the company’s acquisition of Life Technologies, where he
had served as President and Chief Operating Officer. He previously
held the roles of President and Chief Operating Officer of Applied
Biosystems prior to its merger with Invitrogen Corporation.
“At a time in life sciences when technology is playing a more
important role than ever, and the scale of complexity and
innovation is expanding, we are thrilled to welcome Mark,” said
Brett Zbar, MD, Managing Director and Global Head of Life Sciences
at General Atlantic. “Mark has a strong track record leading public
and private companies and driving strategic growth, leveraging his
expertise across many areas within life sciences including genomics
and enabling tools. We believe he will bring great value to our
portfolio and be an important partner to our Life Sciences team in
seeking to identify emerging and compelling opportunities for
investment in what we view as a golden age of biology.”
“I share General Atlantic’s conviction in the large and growing
global opportunity set within life sciences,” said Mark Stevenson.
“I look forward to working with Brett and the General Atlantic team
as we work to identify and support entrepreneurs seeking to scale
the companies that are driving the next wave of biotechnology
innovation.”
Mr. Stevenson received his MBA from Henley Management School and
his bachelor’s degree in Chemistry from the University of Reading.
He is also a board member of several early-stage Life Sciences
companies. He currently serves on the boards of Ingersoll Rand Inc.
(NYSE: IR), Harbinger Health and the Personalized Medicine
Coalition.
General Atlantic formally established Life Sciences as a core
sector in 2020. As of December 31, 2022, General Atlantic has
invested more than $2.5 billion in over 25 companies in the Life
Sciences sector globally.
About General Atlantic
General Atlantic is a leading global growth equity firm with
more than four decades of experience providing capital and
strategic support for over 495 growth companies throughout its
history. Established in 1980 to partner with visionary
entrepreneurs and deliver lasting impact, the firm combines a
collaborative global approach, sector specific expertise, a
long-term investment horizon and a deep understanding of growth
drivers to partner with great entrepreneurs and management teams to
scale innovative businesses around the world. General Atlantic has
more than $72 billion in assets under management inclusive of all
products as of December 31, 2022, and more than 220 investment
professionals based in New York, Amsterdam, Beijing, Hong Kong,
Jakarta, London, Mexico City, Miami, Mumbai, Munich, San Francisco,
São Paulo, Shanghai, Singapore, Stamford and Tel Aviv. For more
information on General Atlantic, please visit:
www.generalatlantic.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230324005094/en/
Mary Armstrong & Jake Barnette media@generalatlantic.com